Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury.
about
PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected miceUse of the Galleria mellonella caterpillar as a model host to study the role of the type III secretion system in Pseudomonas aeruginosa pathogenesisType III secretion proteins PcrV and PcrG from Pseudomonas aeruginosa form a 1:1 complex through high affinity interactionsEffects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat modelTLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxinsAn indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates.Vaccines for Pseudomonas aeruginosa: a long and winding roadV-antigen homologs in pathogenic gram-negative bacteriaAssociation between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a reviewIn the absence of effector proteins, the Pseudomonas aeruginosa type three secretion system needle tip complex contributes to lung injury and systemic inflammatory responsesIntoxication of host cells by the T3SS phospholipase ExoU: PI(4,5)P2-associated, cytoskeletal collapse and late phase membrane blebbingModified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosaProtein binding between PcrG-PcrV and PcrH-PopB/PopD encoded by the pcrGVH-popBD operon of the Pseudomonas aeruginosa type III secretion systemAn adenylate cyclase-controlled signaling network regulates Pseudomonas aeruginosa virulence in a mouse model of acute pneumoniaExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa.Regulatory role of PopN and its interacting partners in type III secretion of Pseudomonas aeruginosaFunctional domains of ExsA, the transcriptional activator of the Pseudomonas aeruginosa type III secretion systemCharacterization of ExsA and of ExsA-dependent promoters required for expression of the Pseudomonas aeruginosa type III secretion system.A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative BacteriaProtection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccinePseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells.Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.Activation of ExoU phospholipase activity requires specific C-terminal regions.Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin proteinProtective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa InfectionDirect neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrVHijacking of the pleiotropic cytokine interferon-γ by the type III secretion system of Yersinia pestisNovel strategies to combat bacterial virulence.Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapyProtective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.Pathogenesis of septic shock in Pseudomonas aeruginosa pneumoniaA secreted regulatory protein couples transcription to the secretory activity of the Pseudomonas aeruginosa type III secretion system.LcrV plague vaccine with altered immunomodulatory propertiesType III secretion: a bacterial device for close combat with cells of their eukaryotic hostEfficient isolation of Pseudomonas aeruginosa type III secretion translocators and assembly of heteromeric transmembrane pores in model membranes.Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU.
P2860
Q24548633-49CCFEDF-7CC0-4711-AA2B-B6FC221339C3Q24682662-B5B38516-5D5D-4072-B71F-73F542B8C90DQ24793790-EEEE68CA-4D0C-4E66-850B-16D883F53BECQ24797978-653FE914-B18C-4BBD-ABA7-8060C81972AAQ24805246-C7EE2AE9-E703-47BF-BCFC-1CCD41F526A6Q25256862-7E46EE6C-73C0-4A17-8EEB-ECBD4C1D712FQ26852817-4B414356-2017-49F1-B451-FA4578A21166Q27008415-4B9AC8EA-BA2A-40EE-8D15-D06242C320D1Q27013824-80C94C93-E32C-4C78-AEEB-5E803426239EQ27300857-7B5A811C-1B1B-4D0D-B5B2-8B6DAD31D263Q27318150-B789A8EB-E0A6-4D68-AAAA-B5F1905ACFAFQ28492629-37060C19-E6E3-4CE3-B8E5-4D4B0DB7D0DBQ28492902-EEEE2413-6046-4399-9C1F-604C3282CA1EQ28492911-F59DE02B-79E2-422A-BE95-97B463024FFBQ28492983-D0A2FD1C-7D3B-40DF-AF3F-EBE0B88437D9Q28493109-FBE79C3A-A8C4-4428-8822-524FA09CC19BQ29346800-03FE336A-28E0-4D57-9F1C-42010F88ED87Q29346817-82725F29-7C90-47F0-B1A7-73389FD3B024Q30408273-7B13509F-CB98-413B-B5F1-C6D7641777A5Q30423024-8BD67B77-1E6D-410C-B29C-F4A278029B28Q30431366-47241965-C558-435B-A2FF-683AB7F08347Q30453151-FDE7AEEF-E56F-4890-A9AF-7920192D64BDQ30453226-CB66574B-6239-4F4E-8810-0E6FEA13E34EQ33178932-8C59D66F-A6D2-4104-ABC4-3A1DF6777187Q33180176-49AF8A8A-22F3-4DDA-909B-38794392D259Q33526200-3800A73B-0AA3-4FC4-860C-509AD9E49BEBQ33553144-43C91CF5-34BF-4215-90E0-719AD4CCAB07Q33553646-002D602F-5EE3-4BE3-9F59-B5EA1D3DC973Q33601814-DDB62A40-D2C6-4395-A280-6FE943C02B0AQ33778441-4E4BD4DA-2A9F-4DC8-8166-059E2EFAA8BFQ33811627-2E504AA6-E9E5-4D9E-BC19-AA643E2FBCA3Q33812082-C9D00A7A-A626-4B5D-9CAD-8A20EF30ADDCQ33822579-8F4B8A69-268C-480A-9813-0516DDF5BC3BQ33836925-DD9C018F-388B-4E89-81CB-E7854FAF85FBQ33853738-2AF67F4E-90A3-4008-9056-5C63F101408EQ33896093-162E5B2D-EEDF-4554-8CE6-D21266D9781FQ33946882-AB92DE1F-2373-404A-BFB5-B6552730041DQ33955524-F7B69131-FA54-44EB-BC53-01E3225326D0Q33965276-747C915E-0ADD-443E-BACB-F9B264333CB9Q33996557-AC17222A-C2D9-4AAC-A18F-7273D7309182
P2860
Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Active and passive immunizatio ...... intoxication and lung injury.
@en
type
label
Active and passive immunizatio ...... intoxication and lung injury.
@en
prefLabel
Active and passive immunizatio ...... intoxication and lung injury.
@en
P2093
P2860
P356
P1433
P1476
Active and passive immunizatio ...... intoxication and lung injury.
@en
P2093
Gropper MA
Kurahashi K
Wiener-Kronish JP
P2860
P2888
P304
P356
10.1038/7391
P407
P577
1999-04-01T00:00:00Z
P6179
1045209097